comparemela.com

Latest Breaking News On - Pembrolizumab - Page 7 : comparemela.com

The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Urothelial carcinomaMetastatic urothelial carcinomaCheckmate 901Platinum based chemotherapyAdverse eventsPd l1

EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA.

Ahsan arozullahPerez valderramaEuropean medicines agencyOncology development at astellasOncology developmentMedicines agencyEnfortumab vedotinMetastatic urothelial cancer

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Martinh vossInternational metastatic renal cell carcinoma database consortiumMerck co incMerck sharp dohmeCancers symposiumGenitourinary medical oncology serviceMemorial sloan kettering cancer centerMerck sharpRhas yNon clear cell rccRenal cell carcinomaPhase 2 keynote b61 trial2024 genitourinary cancers symposiumFirst line pembrolizumab plus lenvatinib

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

United statesDana farber cancer instituteBristol myers squibbNancy kohlbergToni choueiriRoche genentechCalithera biosciencesSanofi aventisMichaelj hennessy associatesGilead sciencesInfinity pharmaceuticalsLank centerKidney cancer programMedicine at harvard medical schoolFoundation medicineNavinata health

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Perez valderramaMichiels vanBristol myers squibbAstellas pharmaGilead sciencesCancers symposiumDer heijdenEnfortumab vedotinAsco guGenitourinary cancers symposiumEv 302Keynote a39 trialMichiels van der heijdenNetherlands cancer instituteSubgroup analysisUrothelial carcinoma

vimarsana © 2020. All Rights Reserved.